Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
The effect of sex steroids on lipid metabolism depends on the type and dose of the compounds, the route of administration, and the duration of treatment. Therefore the composition of an oral contraceptive determines the resultant effect on lipids and lipoproteins. During 12 months of treatment, the effects of two oral contraceptives containing 30 micrograms of ethinyl estradiol and 150 micrograms of desogestrel (EE/DG) or 75 micrograms of gestodene (EE/GSD) on 19 serum parameters of lipid metabolism were followed in 11 women each. There was no change in total cholesterol and phospholipids. Total triglyceride levels were significantly elevated only by EE/GSD. After 3 and 6 months of intake of both preparations, a transitory increase in the triglyceride content of very low-density lipoprotein and low-density lipoprotein and a decrease in low-density lipoprotein-phospholipids was observed. After 12 months, very low-density lipoprotein cholesterol, very low-density lipoprotein phospholipids, and apolipoprotein B were significantly elevated, whereas very low-density lipoprotein triglycerides and all components of low-density lipoprotein were unchanged. Most of the components of high-density lipoprotein (HDL) were increased as a result of a rise in HDL3 and apolipoprotein A2, whereas HDL2 and apolipoprotein A1 were not altered. There was no significant difference between the effects of the two preparations, although those of EE/GSD were mostly more pronounced. The increase in high-density lipoprotein, very low-density lipoprotein, and total triglycerides reflects a slight preponderance of the effect of the estrogen component. Because low-density lipoprotein cholesterol and total cholesterol were not changed, treatment with both formulations is in all probability not associated with an elevated risk of atherosclerosis.
Kuhl
H
H
Department of Obstetrics and Gynecology, J.W. Goethe University, Frankfurt am Main, Federal Republic of Germany.
März
W
W
Jung-Hoffmann
C
C
Heidt
F
F
Gross
W
W
D000293:Adolescent; D000328:Adult; D001161:Arteriosclerosis / Q000453:epidemiology; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000494:pharmacology*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000494:pharmacology*; D017135:Desogestrel; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D009652:Norpregnenes / Q000494:pharmacology; D045167:Progesterone Congeners / Q000494:pharmacology; D012016:Reference Values; D012307:Risk Factors; D013997:Time Factors
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D008055:Lipids; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D004997:Ethinyl Estradiol; D017135:Desogestrel